

## FREQUENCY AND ANTIBIOTIC SUSCEPTIBILITY PATTERN OF ACINETOBACTER SPP ISOLATED FROM PUS AND WOUND SWABS (A TERTIARY CARE EXPERIENCE)

KOKAB JABEEN<sup>1</sup>, SUMMAYA SIKANDAR BEG<sup>2</sup>, FAREEHA IMRAN<sup>3</sup>, AASMA NOVEEN AJMAL<sup>4</sup>, FARHANA IMRAN<sup>5</sup>

<sup>1,2</sup>Assistant Professor Pathology, Fatima Jinnah Medical University Lahore. <sup>3,4</sup>Senior Demonstrator, Ameer ud Din Medical College, Lahore. <sup>5</sup>Senior Demonstrator, Allama Iqbal Medical College, Lahore.

### ABSTRACT

**Background:** For the past two decades, *Acinetobacter* spp. has emerged as an important pathogen globally in various infections mostly in hospital settings.

**Objectives:** This study was conducted to determine the frequency and antibiotic susceptibility pattern of *Acinetobacter* spp isolated from pus and wound swabs.

**Methods:** This retrospective cross-sectional study included a total of 110 Pus and wound samples collected from patients presenting to Fatima Jinnah Medical University, Lahore laboratory from Jan 2016 to March 2016. The samples were processed and identified by standard protocol. The *Acinetobacter* isolates were tested for antibiotic resistance by Kirby-Bauer disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.

**Results:** From 110 wound samples, 87 (79%) showed significant growth of 87 positive cultures 20 samples (23%) showed growth of *Acinetobacter*, 11(12.7%) *Klebsiella* Spp 22(25.3%) *Staphylococcus* Spp 18 (20.6%) *Pseudomonas* Spp and 16 (18.4%) *Escherichia coli*. Out of 20 isolates of *Acinetobacter*, 13 (65%) were resistant to more than three classes of antibiotics (multidrug resistant) and 3 (15%) were resistant to all commonly used antibiotics (pan-drug resistant). Majority of the isolates were sensitive to Imipenem, Amikacin and Tigecycline and showed resistance rates of 45%, 50%, and 45%, respectively.

### Conclusion:

This hospital-based epidemiological data will help to implement better infection control strategies and improve the knowledge of antibiotic resistance patterns in our region.

**Keywords:** *Acinetobacter* species, antibiotics, frequency, resistance

**How to cite this article:** Jabeen K, Beg SS, Imran F, Ajmal AN, Imran F. Frequency and Antibiotic Susceptibility Pattern of *Acinetobacter* Spp Isolated from Pus and Wound Swabs: Tertiary Care Experience. Pak Postgrad Med J 2019;30(4): 135-138

---

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

Correspondence to: *Kaukab Jabeen*  
Assistant Professor, Department of Pathology,  
Fatima Jinnah Medical University Lahore, Pakistan.

Email: [kaukab\\_jabeen@yahoo.com](mailto:kaukab_jabeen@yahoo.com)

### INTRODUCTION

*Acinetobacter* species are free-living and saprophytic bacilli that can be obtained easily from soil, water, food, and sewage<sup>1</sup>. These are aerobic, gram-negative, non-fermenter of glucose, and opportunistic pathogens that emerge as an important

cause of hospital-acquired infections. *Acinetobacter* has undergone significant taxonomic modification over the last 30 years. Its most common and important representative is *Acinetobacter baumannii*, and the other species such as *Acinetobacter lwoffii*, *Acinetobacter johnsonii*, and *Acinetobacter haemolyticus* are rarely isolated from patients<sup>2</sup>. Its great capacity to survive in low-moist environment coupled with its ability to develop resistance to antimicrobial agents can increase the possibility of spreading in hospitals<sup>3</sup>. The nosocomial infections caused

by *Acinetobacter* include pneumonia, septicemia, wound sepsis, urinary tract infection, endocarditis, and meningitis<sup>4</sup>. In addition to infection among hospitalized patients, community-acquired *Acinetobacter* infection is increasingly reported<sup>5</sup>. There is a significant difference in the behavior and spread of multi-drug resistant *Acinetobacter* spp recovered various geographic locations<sup>6</sup>. Since several factors cause resistance in *Acinetobacter* spp., treatment of infections caused by this organism should be based on antibiotic susceptibility tests. Therefore, having information regarding the prevalence and pattern of bacterial resistance to these drugs is important<sup>7, 8</sup>.

**METHODS**

A retrospective, hospital record-based, cross-sectional study was carried out from Jan 2016 to March 2016 in Pathology Department of Allama Iqbal Medical College Lahore. A total of 110 wound samples were collected. A retrospective evaluation of patient's age and sex was carried out on the basis of the case record histories. A healthcare-associated infection or nosocomial infection is defined as a localized or systemic condition resulting from an adverse reaction to the presence of an infectious

agent (s) or its toxin (s) that was not present on admission to the hospital.<sup>9</sup>

In the laboratory, all the collected samples were cultured aerobically on blood agar and MacConkey agar. All isolates were tested for antimicrobial susceptibility testing by the standard Kirby-Bauer disk diffusion method.<sup>10</sup> The following standard antibiotic disks were placed on the MHA plate: Augmentin (10ug), Ciprofloxacin (5ug), Amikacin (30ug), Ceftazidime (30ug), Imipenem (10ug), Ceftriaxone (30ug) and Tigecycline(15ug).The plate was incubated at 37°C overnight. The zone of inhibition were measured and interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.<sup>11</sup>The isolate was considered as highly resistant when it was resistant to Imipenem, Amikacin, and Augmentin. Multidrug-resistant (MDR) *Acinetobacter* spp. are defined as those isolates resistant to more than three classes of antibiotics. An isolate was classified as pan-resistant when it was resistant to all the commonly used antibiotics.<sup>12</sup>




Figure 1: Frequency of bacterial pathogens in pus and wound swabs.

**RESULTS**

Out of 110 samples, 77 were from males and 33 from females. During the study period from Jan 2016 to March 2016, a total of 110 wound samples were aerobically cultured, of which 87 (79%) yielded significant growth and rest of the samples 23 (21%) showed non-significant growth. Of 87 positive cultures

20 samples (23%) showed growth of *Acinetobacter SPP*, 11(12.7%) *Klebsiella SPP*, 22(25.3%) *Staphylococcus SPP*, 18(20.6%) *Pseudomonas SPP* and 16(18.4%) *Escherichia coli*

In the present study, most of the *Acinetobacter* spp. were highly resistant to Ceftazidime (100%), Augmentin (100%), Ceftriaxone (90%), Ciprofloxacin (80%), Amikacin (50%), Imipenem (45%) and Tigecycline (45%) The low resistant patterns of imipenem (45%), Tigecycline (45%) and

Amikacin indicate that they are effective drugs. The study showed that 65% isolates were multi-drug resistant.

Table 1: Antibiotic resistance profile of *Acinetobacter spp*

Antibiotics	Frequency	Percentage
Augmentin	20	100%
Ceftazidime	20	100%
Ceftriaxone	18	90%
Amikacin	10	50%
Ciprofloxacin	16	80%
Imipenem	9	45%
Tigecycline	9	45%

Table 2: Distribution of resistance in *Acinetobacter Spp*

Susceptibility pattern	No of isolates	Percentage
Sensitivity	4	20%
Multi drug Resistant	13	65%
Pan drug resistant	3	15%

In our study, most of the isolates were multi-drug resistant. Only 20% were sensitive while 65% were multi-drug resistant and 15% were resistant to all the antibiotics.

## DISCUSSION

*Acinetobacter spp* are the second most common non-fermenting bacteria after *Pseudomonas* species that are isolated from human specimens, especially among nosocomial infections.<sup>13</sup> In recent years, this species has emerged as the causative agent of important nosocomial infections in the ICUs and emergency unit, which is probably related to the increasingly invasive diagnostic procedures used, the greater quantity of broad-spectrum antimicrobials used, and prolonged duration of stay in the hospital. Development of resistance against antimicrobials is a major problem in the treatment of *Acinetobacter* infections. Although they are considered as pathogen of mild virulence, they can rapidly acquire resistance.<sup>14</sup>

In our study, from 110 wound samples 20 (23%) *Acinetobacter spp* was obtained. In the present study, most of the *Acinetobacter spp.* was highly resistant to ceftazidime, augmentin, ceftriaxone and ciprofloxacin. The low resistant patterns of Imipenem, Tigecycline and Amikacin indicate that they are effective drugs. A similar result was obtained from a study conducted at a tertiary care hospital PIMS Islamabad from Feb 2011 to Dec 2011 where the prevalence of *Acinetobacter* was

reported to be 16.48% in wound specimens. Most of the isolates were multi-drug resistant. The antibiotic susceptibility profile showed that minocycline and tigecycline were the most effective against *A. baumannii*.<sup>15</sup> A similar study was conducted at Institute of Molecular Biology and Biotechnology, The University of Lahore where the prevalence of *Acinetobacter Spp* in wound specimens was 25%. The multidrug resistance pattern showed 98.75% resistance to Ceftazidime, 88.75% resistance to Ciprofloxacin, 97.5% resistance to Cefotaxime and 77.5% for imipenem. It showed sensitivity to Tetracycline derivative i.e., Tigecycline (52.5%). These results are similar to our results.<sup>16</sup> In a study conducted at Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India the prevalence of *Acinetobacter Spp* in wound specimens was 20% while 77% isolates were MDR which is similar to our results.<sup>17</sup> *Acinetobacter* is ubiquitous in the hospital setting. Its ability to survive for long periods coupled with its ability to demonstrate a number of antimicrobial resistance genes has made *Acinetobacter* a successful hospital pathogen.<sup>3</sup>

Most of the patients who were admitted in our hospital had previously attended primary and secondary care hospitals and usually received combination of  $\beta$ -lactam antibiotics like third- and fourth-generation Cephalosporins along with Aminoglycosides or Fluoroquinolones. Thus, majority of the isolates in our study were resistant to commonly used antibiotics such as Ceftazidime, Ceftriaxone, Amikacin, Ciprofloxacin and Augmentin. This means MDR isolates are increasing day by day, probably due to indiscriminate use of these antibiotics in healthcare settings. It is re-emphasized that broad-spectrum antibiotics should be used with caution. There are many measures that may impact on antimicrobial resistance; reducing and restricting the use of antimicrobials to only those situations where they are warranted, at proper dose and for the proper duration is the most appropriate solution.<sup>18</sup>

## CONCLUSION

The high prevalence of the organism in clinical specimens together with its multidrug resistance has made *Acinetobacter baumannii* an important nosocomial pathogen leading to significant morbidity and mortality. A combination of a review of hand-washing practice, education about the spread of bacteria via hands and contaminated environment, and the revision of infection control procedures would help in the control of this organism in

hospitals. To avoid resistance, antibiotics should be used judiciously and empirical antibiotic therapy should be determined for each hospital according to the resistance rates of that center. This should be regulated according to antibiogram results. Increasing Carbapenem resistance rates in *Acinetobacter* spp. leads to usage of new alternative antibiotics like Tigecycline.

## REFERENCES

1. Dougari HJ, Ndakidemi PA, Human IS, Benade S. Virulence factors and antibiotic susceptibility among verotoxic non O157: H7 *Escherichia coli* isolates obtained from water and waste water samples in Cape Town, South Africa. *Afr J Biotechnol.* 2011; 10:14160–8.
2. Peleg AP, Seifert H, Paterson DL. *Acinetobacter baumannii* Emergence of a successful Pathogen. *Clin Microbiol Rev.* 2008; 21:538–582.
3. Yu Yu, Yang Q, Xu Xw, Kong HS, Xu GY, G BY. Typing and characterization of carbapenems resistant *Acinetobacter calcoaceticus – baumannii* complex in a Chinese hospital. *J Med Microbiol.* 2004; 53:653–656.
4. Towner KJ. Clinical importance and antibiotic resistance of *Acinetobacter* spp. *J Med Microbiol.* 1997; 6:186–197.
5. Leung WS, Chu CM, Tsang KY, Lo FH, Ho PL. Fulminant community-acquired *Acinetobacter baumannii* pneumonia as a distinct clinical syndrome. *Chest.* 2006; 129:102–109.
6. Houang ET, Chu YW, Leung CM, Chu KY, Berlau J, Ng KC, et al. Epidemiology and infection control implication of *Acinetobacter* spp. in Hong Kong. *J Clin Microbiol.* 2001; 39:228–234.
7. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among *Acinetobacter calcoaceticus-baumannii* complex and Enterobacteriaceae collected as a part of yhe tigecycline evaluation and surveillance trail. *J Infect.* 2007; 55:49–57.
8. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, et al. An outbreak of multidrug-resistant *Acinetobacter baumannii-calcoaceticus* complex infection in the US military health care system associated with military operations in Iraq. *Clin Infect Dis.* 2007; 44:1577–1584.
9. Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting; c2013. [Last updated on 2013 April; cited on 2013 April 28].
10. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol.* 1966; 45:493–496.
11. CLSI document M100-S19. Wayne; PA: USA: Clinical and Laboratory Standards Institute; 2009. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Nineteenth Informational Supplement.
12. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant *Acinetobacter baumannii*: A descriptive study in a city hospital. *BMC Infect Dis.* 2010; 10:196.
13. Getchell-White SI, Donowitz LG, Gröschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: Evidence for long survival of *Acinetobacter calcoaceticus*. *Infect Control Hosp Epidemiol.* 1989; 10:402–407.
14. Appleman MD, Belzberg H, Citron DM, Heseltine PN, Yellin AE, Murray J, et al. *In vitro* activities of nontraditional antimicrobials against multiresistant *Acinetobacter baumannii* strains isolated in an intensive care unit outbreak. *Antimicrob Agents Chemother.* 2000; 44:1035–1040.
15. Shahzeera B, Fariha H, Shagufta H, Prevalence of multi drug resistant *Acinetobacter baumannii* in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan, *Pak J Med Sci.* 2013; 29(5): 1253–1258.
16. Saba S, Mohsin A, Mahmmod Q. Prevalence of Multidrug Resistant *Acinetobacter baumannii* in Hospitalized patients in Lahore, Pakistan. *J Mol, Med.* 2015; 2(1): 23–28.
17. Sudhaharan S, Vemu L, Kanne P. Prevalence of multi drug resistant *Acinetobacter baumannii* in a tertiary care hospital, *Int J Infect Control.* 2014; 11(3): 506–509.